Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Isatuximab in Relapsed or Refractory T-ALL or T-LBL
2016-002739-14Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Sanofi. Primary endpoint: Objective response rate. Started Oct 2016; status: terminated.
02
Drugs
isatuximab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2016-002739-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002739-14.